We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+16.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.73B
AUM Growth
+$239M
(+16%)
Cap. Flow
+$39.4M
Cap. Flow
% of AUM
2.27%
Top 10 Holdings %
Top 10 Hldgs %
27.21%
Holding
142
New
9
Increased
33
Reduced
17
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$27.4M |
| 2 |
Johnson & Johnson
JNJ
|
+$20.9M |
| 3 |
Pacira BioSciences
PCRX
|
+$12.4M |
| 4 |
AFAM
Almost Family Inc
AFAM
|
+$10.8M |
| 5 |
OBSV
ObsEva SA Ordinary Shares
OBSV
|
+$10.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$27.7M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$22.6M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$12.3M |
| 4 |
Medpace
MEDP
|
+$4.87M |
| 5 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$3.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.21% |
| 2 | Financials | 2.45% |
| 3 | Consumer Discretionary | 0.63% |
| 4 | Industrials | 0.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Novavax
NVAX
$1.31B
| $1.05M | 0.06% |
41,000
| – | – |
|
127
Perrigo
PRGO
$1.78B
| $1.04M | 0.06% |
15,600
+6,300
| +68% | +$479K |
|
|
DVAX
128
DELISTED
Dynavax Technologies
DVAX
| $982K | 0.06% |
165,000
| – | – |
|
|
INFI
129
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $872K | 0.05% |
270,000
| – | – |
|
|
CHMA
130
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $837K | 0.05% |
492,500
| – | – |
|
131
Bausch Health
BHC
$2.34B
| $732K | 0.04% |
66,400
-5,000
| -7% | -$68.8K |
|
132
Tandem Diabetes Care
TNDM
$1.56B
| $714K | 0.04% |
59,500
| – | – |
|
|
OREX
133
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $569K | 0.03% |
165,300
| – | – |
|
|
ANTH
134
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $552K | 0.03% |
162,071
+114,571
| +241% | +$542K |
|
135
Dare Bioscience
DARE
$21M
| $508K | 0.03% |
5,208
| – | – |
|
|
DMTX
136
DELISTED
Dimension Therapeutics, Inc
DMTX
| $475K | 0.03% |
271,370
| – | – |
|
|
137
Medpace
MEDP
$16.5B
| – | – |
-135,000
| Closed | -$4.87M |
|
|
ARIA
138
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| – | – |
-250,000
| Closed | -$3.11M |
|
Similar funds
ACM
BCM
PP
GAM
FACM
RMC
JIP
II
Rock Springs Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, Rock Springs Capital Management held 142 positions worth $1.73B, up 16% from $1.49B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Rock Springs Capital Management's Q1 2017 filing shows 9 new, 33 increased, 17 reduced and 2 closed positions. Its largest new stake was Humana: 132,500 shares worth $27.3M. The largest sale was Aetna Inc, an estimated $27.7M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Financials and Consumer Discretionary.
- Rock Springs Capital Management's largest Q1 2017 buy was Humana: 132,500 shares worth $27.3M.
- Rock Springs Capital Management added most to Pacira BioSciences in Q1 2017, an estimated $12.4M increase.
- Rock Springs Capital Management's biggest Q1 2017 reduction was Aetna Inc, cutting an estimated $27.7M.
- Rock Springs Capital Management fully exited Medpace in Q1 2017, selling an estimated $4.87M.
- Rock Springs Capital Management's ten largest holdings make up 27% of its $1.73B portfolio in Q1 2017.
- Rock Springs Capital Management opened 9 new positions and closed 2 in Q1 2017.
- Rock Springs Capital Management's portfolio value rose 16% quarter-over-quarter to $1.73B.
Based on Rock Springs Capital Management's 13F filing for Q1 2017, filed 15 May 2017.